NB-110

NB-110 is an investigational ophthalmic drug being developed by Adtech Pharma for the treatment of glaucoma, with a dual aim of lowering intraocular pressure (IOP) and protecting optic nerves from glaucomatous damage. Preclinical findings reported by the company indicate that NB-110 reduces IOP and may confer neuroprotective effects on the optic nerve, a combination that is described as differentiating it from existing glaucoma therapies that primarily focus on IOP reduction alone.[1][5][7] Detailed molecular structure, target, and modality have not been publicly disclosed, and the program appears to be in the preclinical stage without registered clinical trials.